Who is buying UK online pharmacies, and why?

Is UK online pharmacy consolidating?

Yes — at every layer of the market, and faster than the wider pharmacy sector. Data from accountancy firm UHY Hacker Young recorded 1,212 UK pharmacies acquiredin the twelve months to June 2024, a 50% increase on the 809 acquired the year before. That means roughly 9% of the entire network changed hands in a single year. The broader deal environment has stayed hot. Grant Thornton's healthcare M&A review counted 114 UK healthcare and pharma services deals in the first quarter of 2026, up 37% on the same period a year earlier. Private equity and venture-backed deals were up 43%, as financial investors backed what one report called the sector's defensive resilience. A recurring theme in that analysis is providers using acquisition to diversify away from NHS revenue — which is the online pharmacy story in one sentence.

The online segment's own deal record tells the story more precisely than the aggregates. Between October 2023 and February 2026, the UK's largest online pharmacy made at least six acquisitions. The most recognisable name in British pharmacy was taken private. The remains of the second most recognisable were sold in pieces to its digital rival, and two of the largest US consumer health companies bought their way into the UK cash-pay market. None of this happened by coincidence, and the buyers are not all playing the same game. Working out which game each is playing is the useful part.

Who is buying: the NHS-volume consolidator

The first buyer logic is scale in NHS dispensing, and Pharmacy2U is its defining practitioner. The company is backed by private equity firm G Square Capital and merged with ChemistDirect back in 2016. In October 2023 it acquired LloydsDirect, the distance selling pharmacy formerly known as Echo, adding more than 500,000 repeat prescription patients. Lloyds Pharmacy's Online Doctor service followed in February 2025. During the 2024/25 financial year it added pet prescription business The PharmPet Co and GP-support provider Medicines Management Solutions. Then came care home specialist Care Quality Pharmacy in January 2026 — a deal its chief executive framed explicitly as extending into a market responsible for an important share of all UK dispensing.

The results, from its own Companies House filings as reported by The Pharmaceutical Journal in January 2026, show what the strategy buys. Pharmacy2U dispensed 31.2 million NHS prescriptions in 2024/25, up 64.5% from 19.0 million the year before. NHS patient nominations rose from 814,000 to 1.5 million. Revenue grew 68% to £334 million. And the company still recorded a £5.7 million pre-tax loss.

That last number is the strategically interesting one, and it should be read as information rather than weakness. Dispensing NHS prescriptions pays the same Single Activity Fee whether you dispense a thousand items or thirty million. So a volume model wins by amortising automation, logistics and acquisition costs across a nomination base big enough to turn thin per-item margins into a business. The loss tells you the base is not there yet. The acquisition pace tells you the plan is to buy the rest of the way. For everyone else in the market, the practical implication is blunt. Competing head-on with this model on NHS repeat volume means competing with a buyer of scale, on margins set by the Drug Tariff, without the automation. That is not a fight most independents should pick, and later sections return to what they should do instead.

Who is buying: US capital and the private-services land grab

The second buyer logic is access to British and European cash-pay patients, and the buyers are American. Hims & Hers, the US direct-to-consumer telehealth company, entered the UK by acquiring London-based Honest Health in 2021. In June 2025 it announced the all-cash acquisition of Zava, one of Europe's largest digital health platforms, with around 1.3 million active customers across the UK, Germany, France and Ireland and nearly 2.3 million consultations delivered in 2024. In February 2026 it went again. It acquired Australia's Eucalyptus — operator of the Juniper weight management brand that is prominent in the UK — in a deal reported at $1.6 billion.

Why does a US company pay those prices for European operations? No mystery — its chief executive has explained it publicly. Pharmaceutical pricing in Europe is more consumer-advantageous than in the US, statutory health systems are strained in ways telehealth can arbitrage, and demand, particularly for weight management, is enormous and growing. What is being bought is not primarily brand. It is regulated market access: GPhC-registered pharmacy operations, prescriber networks, clinical governance that satisfies the February 2025 distance selling guidance, and a customer base already comfortable paying out of pocket. Those assets take years to build and one transaction to buy. The economics covered in our analysis of the weight management boom explain the urgency.

The backdrop completes the picture. Walgreens Boots Alliance, owner of the most famous name in UK pharmacy, was taken private by Sycamore Partners in a deal completed in August 2025 — part of a broader pattern of large-scale restructuring away from public markets. When the biggest incumbent is restructuring and the fastest capital is American, the middle of the market gets squeezed from both ends. That is precisely where most UK online pharmacies sit.

What is actually being bought

Underneath every one of these deals, a small set of assets is changing hands, and naming them clarifies the whole market. The first is the nomination base. Under the Electronic Prescription Service (EPS), a patient's nomination directs their repeat prescriptions to one pharmacy month after month. A nominated patient is an annuity. The Competition and Markets Authority's own decision on the Pharmacy2U and LloydsDirect merger analysed the deal substantially through where nominations transfer when pharmacies compete. Nominations are the closest thing NHS pharmacy has to recurring revenue. That is why they are what volume buyers are really purchasing.

The second is regulatory infrastructure: GPhC-registered premises, superintendent arrangements, distance selling compliance and prescriber governance. As our analysis of GPhC enforcement priorities set out, the regulator has made online pharmacy governance expensive to build and evidence. That, perversely, raises the acquisition value of anyone who has already built it. The third is physical capacity — the automated dispensing hubs that make 31 million items a year possible. The fourth is trust equity: the accumulated reviews, clinical reputation and domain authority that Google's trust framework rewards, and that cannot be bought except by buying the company. And the fifth, increasingly, is the software layer itself. In March 2026, private equity firm TPG acquired EMIS, whose systems sit under more than half of English general practice. Consolidation is happening in the infrastructure your pharmacy runs on, not just among your competitors.

Why sellers are selling

The supply of sellers is a funding story, and it is the same one behind every article in this series. UHY Hacker Young's benchmarking found gross profit per pharmacy fell 10% in a year, to £382,468. Community Pharmacy England's 2025 survey found only 6% of owners describing their business as profitable. And the Frontier Economics analysis commissioned by NHS England found a £2.3 billion annual gap between what pharmacies cost to run and what the NHS pays.

The Lloyds arc is the era's defining case study. Aurelius Asset Management acquired the LloydsPharmacy business in April 2022. Within two years, the estate of more than a thousand community branches had been sold off and liquidation proceedings had begun. The digital assets were sold separately: the LloydsDirect distance selling business to Pharmacy2U in October 2023, and the Online Doctor service to the same buyer in February 2025. A brand that had anchored British high-street pharmacy for decades was disassembled into its component assets. The component that held its value best was the online patient base. Every independent owner weighing their own future should notice which parts of that business the market wanted.

What the CMA position means

The competition regulator has looked hard at online pharmacy consolidation once, and it cleared the deal. That sets the current weather. When Pharmacy2U completed its acquisition of LloydsDirect in October 2023, the CMA served an initial enforcement order in November 2023 and opened a formal phase 1 investigation in January 2024. It examined internal documents, customer switching data and third-party evidence, with competitors and the parties treating each other as closest rivals. It cleared the merger in March 2024, resting substantially on the fragmentation of the wider dispensing market. The merged business held a small share of total dispensing, and patients switching nominations moved to bricks-and-mortar pharmacies as well as online ones. The constraint on the merged entity therefore came from the whole market, not only from other distance sellers.

Two practical readings follow. First, the clearance suggests considerable headroom for further online consolidation while the analysis treats bricks-and-mortar dispensing as a genuine competitive constraint. But that logic weakens as online share grows. So the regulatory risk on future deals rises with the very consolidation the clearance permits. Second, competition clearance is not the only gate. Pharmacy2U was separately refused a change of ownership of a LloydsDirect premises in west London, through the NHS market-entry system and on appeal in August 2024. NHS pharmaceutical list regulations move on their own track, and buying a company does not automatically transfer its NHS listings. Deal certainty in this sector requires both regimes, and advisers who know only one of them miss real risk.

The deal record, 2021 to 2026

What consolidation means if you are not selling

The strategic read for an independent is that the consolidators have chosen their ground, and it is not ground you should contest. Nomination-scale NHS repeat dispensing now belongs to automation economics. US-backed platforms will outspend anyone on national customer acquisition for commodity private services. What neither model localises well is depth: clinical relationships, complex and regulated service lines run properly, care home and clinic relationships in a defined geography, and the kind of governance file that survives inspection because the superintendent actually built it. The GPhC's April 2026 weight management review documented exactly where high-volume transactional models fail. Those failure modes are the independent's opening, because trust and clinical quality do not scale by acquisition.

The defensible position, concretely, is the one this series keeps arriving at from different directions. Build private service lines with real verification and monitoring, a website that works as clinical infrastructure rather than a brochure, and records systems that make quality visible.

Watch the software layer with the same attention you watch competitors. When your PMR or your GP-side integration partner changes ownership, someone else is negotiating your roadmap and your data terms. That is an argument for owning your patient relationships and your data portability, whatever platform you sit on.

Where the next deals come from

The reasoned expectation, stated as expectation rather than fact, is that the next wave of targets sits where private demand meets fragmented supply. Weight management operators are the obvious category: the market dynamics covered in article three, a fivefold rise in regulatory concerns and rising compliance costs favour consolidation into fewer, better-governed platforms, and Hims & Hers has already bought two routes into it. Care-adjacent dispensing is likely to follow Care Quality Pharmacy's precedent, since care home volume is contracted, sticky and operationally suited to hub dispensing. Specialist clinical niches, from ADHD pathways to hormone services, offer the same combination of cash-pay demand and governance barriers that makes builders valuable to buyers. And the steady exit of underfunded independents will continue supplying the volume consolidators unless the funding settlement changes materially, which the 2026/27 agreement, for all its 10.3% uplift, did not.

None of this is deterministic. A CMA that grows less comfortable as online share rises, a funding settlement that genuinely restores independent margins or a regulatory event in weight management could each slow the machine. But the direction has three years of deal record behind it, and the sensible planning assumption for any owner is that the consolidation continues and the choice is the one this article started with: build private revenue, achieve scale or exit, and make the choice deliberately rather than having it made for you.

Key takeaways

FAQs